Identifying BRAF as a key target for the development of novel cancer therapeutics
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 5 - Biological Sciences
- Summary impact type
- Technological
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- Yes
- Underpinning research subjects
-
- Biochemistry And Cell Biology
- Clinical Sciences
- Oncology And Carcinogenesis
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
| Grant number |
Value of grant |
| C5759/A3995 |
£170,603 |
| C5759/A5714 |
£47,883 |
| C1364/A6473 |
£110,992 |
| C107/A10433 |
£13,255,685 |
| 071487/Z/03/A |
£50,201 |
| 080333/Z/06/Z |
£2,292,192 |
| C309/A8274 |
£29,156,418 |
| 09-0773 |
£196,852 |
| CTR-Q3-Y1 |
£5,900,000 |
| CTR-Q3-Y2 |
£23,200,000 |
| INT - HER 07/08 |
£192,094 |
| GF011 |
£392,147 |
| C107/A3955 |
£1,496,294 |
| C107/A18577 |
£193,757 |
| 096444/Z/11/Z |
£3,004,236 |
| None given |
£10,000 |
| A17240 |
£0 |
| BRC-2011-10059 |
£61,543,735 |
| 651 CL-2008-22-001 |
£7,004 |
| C309/A11566 |
£40,964,687 |
- Countries
-
- US
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Iceland
- Liechtenstein
- Norway
- UK
- Japan
- Australia
- Canada
- Switzerland
- Formal partners
-
- The Wellcome Trust Sanger Institute
- University of Manchester
- The Wellcome Trust
- Funding programmes
-
- Cancer Research UK: Inhibitors of Activated BRAF
- Cancer Research UK: Inhibitors of BRAF
- Cancer Research UK: Inhibitors of Oncogenic BRAF
- Cancer Research UK: Cell and Molecular Biology - Tumour Cell Signalling Networks
- Wellcome Trust: Inhibitors of BRAF
- Wellcome Trust: Development of 2 Series of Systemic/Oral Inhibitor
- Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2006 to 2011)
- Worldwide Cancer Research: AMPK signalling in melanoma: biology and therapeutic opportunities
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2010 to 2011
- Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2011 to 2015
- Breast Cancer Now (previously Breakthrough Breast Cancer): Identification and functional validation of additional therapeutic targets in HER2 amplified breast cancers
- Cancer Research UK: Marshall Gibb Fellowship (1998)
- Cancer Research UK: Marshall Gibb Fellowship (2002)
- Cancer Research UK: Marshall Gibb Fellowship (2014)
- Wellcome Trust: Preclinical and Clinical Development BRAF Inhibitors
- Cancer Research UK: 2010 Future Leaders Prize in Cancer Research
- Cancer Research UK: Molecular Oncology Group funding
- The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2012)
- National Institute of Health Research: Academic Clinical Lecturer (ACL)
- Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2011 to 2017)
- Global research identifiers
-
- grid.11485.39
- grid.52788.30
- grid.453093.8
- grid.458394.7
- grid.451056.3
- Name of funders
-
- Cancer Research UK
- Wellcome Trust
- Worldwide Cancer Research (previously AICR)
- Breast Cancer Now (previously Breakthrough Breast Cancer)
- National Institute for Health Research
- Researcher ORCIDs
-
- 0000-0001-7484-4183
- 0000-0001-8810-950X
- 0000-0002-0650-4002
- 0000-0001-6035-153X
